摘要
目的 探讨依那普利联合阿托伐他汀钙治疗早期糖尿病肾病的临床疗效.方法 将126例早期糖尿病肾病患者随机分为对照组、依那普利组及联合治疗组,比较三组患者治疗前后血糖、血脂及肾功能指标.结果 三组治疗后FBG、HbA1c差异无统计学意义（P〉0.05）;依那普利组、联合治疗组TC、TG、Cys-C、Scr、U-mA1b、β2-MG较治疗前下降,HDL-C上升,差异具有统计学意义（P〈0.05）;治疗后联合治疗组TC[（4.03±0.37） mmol/L]、TG[（1.33±0.25）mmol/L]、Cys-C[（1.63±0.16） mg/L]、Scr[（75.33±12.87）μmol/L]、U-mA1b[（150.06±13.88） mg/L]、β 2-MG[（2.57±0.93） mg/ml]较依那普利组、对照组下降,而HDL-C[（1.68±0.63） mmol/L]升高,差异具有统计学意义（P〈0.05）,且无不良反应发生.结论 依那普利联合阿托伐他汀钙治疗早期糖尿病肾病可明显抑制脂代谢紊乱,保护肾脏,延缓肾损害发展进程.
Objective To explore the clinical efficacy of enalapril in the combination with atorvastatin calcium for early diabetic nephropathy.Methods 126 patients with early diabetic nephropathy were randomly divided into a control group, an enalapril group, and a combination group.The blood glucose, blood lipid, and renal indexes were compared between these three groups before and after the treatment.Results After the treatment, there were no statistical differences in FBG and HbA1c between these three groups （P〉0.05）.TC, TG, Cys-C, Scr, U-mA1b, and beta 2-MG were lower and HDL-C was higher after than before the treatment in the enalapfil group and the combination group, with statistical differences （P〈0.05）.After the treatment, TC[（4.03±0.37） mmol/L], TG[（1.33±0.25） mmol/L], Cys-C[（1.63±0.16） mg/L], Scr[（75.33±12.87） μmol/L], U-mA1b[（150.06±13.88） mg/L], and β2-MG[（2.57±0.93）mg/ml] were lower and HDL-C[（1.68±0.63） mmol/L] was higher in the combination group than in the enalapril group than the control group, with statistical differences （P〈0.05）.Conclusions Enalapril in the combination with atorvastatin calcium for early diabetic nephropathy can obviously inhibit lipid metabolism disorder, protect kidney, and delay renal damage development process.
出处
《国际医药卫生导报》
2015年第19期2884-2886,共3页
International Medicine and Health Guidance News
